copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . . Anonymous board for AstraZeneca We hope all celebrating Thanksgiving have a safe and enjoyable holiday To allow our employees to enjoy the holiday with their families, the message boards will be set to read-only on Thursday, 11-27-25 from 3:00-9:00 PM ET You can still search and read posts during this time, but posting will be unavailable Thank you for your support!
AstraZeneca | Cafepharma AstraZeneca’s quarterly revenue crossed the $15-billion mark for the first time, giving renewed hope to the company's target of reaching $80 billion in annual sales by the end of the decade "The strong underlying momentum across our business…sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition," remarked CEO Pascal Soriot on Thursday
November 6 2025 - With 2030 ambitions in view, AstraZeneca’s quarterly . . . With 2030 ambitions in view, AstraZeneca’s quarterly revenue passes $15B for first timeAstraZeneca boardEli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3Eli Lilly boardNovartis’ Pluvicto heavywork proves radiopharma can succeedNovartis boardJ J adds first new indication for Caplyta since takeover
Fasenra | Cafepharma AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype A phase III clinical trial is now underway to test the effectiveness of Fasenra in COPD
AstraZenecas Fasenra (benralizumab) Fails Ph III Trial for COPD AstraZeneca and MedImmune, announced on 5 11 18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD
retaliation claims | Cafepharma After AstraZeneca and a former manager-turned-whistleblower each scored partial wins in a retaliation and age discrimination lawsuit, AstraZeneca has nabbed a victory in appeals In the case of Suzanne Ivie, who sued AstraZeneca alleging the company fired her after she raised concerns about off-label marketing, an appeals court has vacated a jury's $2 4 million verdict against the drugmaker
baxdrostat | Cafepharma AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for regulatory filings this year